Oncoarendi Therapeutics S.A.
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded as renamed to Molecure S.A. (2022)
0
Ending by 2030
Dec 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 25, 2026The maintenance fee for Arginase inhibitors and their therapeutic applications (US 10,329,310) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
- 1 fee due Feb 27, 2027The maintenance fee for Arginase Inhibitors and Their Therapeutic Applications (US 10,391,077) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
- 1 fee due Mar 5, 2027The maintenance fee for Process for the Production of 5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-Methyl-MORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-Triazol-3-Amine (US 11,746,107) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,440,953 | Substituted amino triazoles useful as acidic mammalian chitinase inhibitors In force · USPTO record | In force | USPTO record | |
| US 10,329,310 | Arginase inhibitors and their therapeutic applications In force · USPTO record | In force | USPTO record | |
| US 10,912,755 | Arginase Inhibitors and Their Therapeutic Applications In force · High confidence | In force | High confidence | |
| US 10,391,077 | Arginase Inhibitors and Their Therapeutic Applications In force · High confidence | In force | High confidence | |
| US 12,053,451 | Arginase Inhibitors and Their Therapeutic Applications In force · High confidence | In force | High confidence | |
| US 10,851,099 | Dipeptide piperidine derivatives In force · USPTO record | In force | USPTO record | |
| US 11,746,107 | Process for the Production of 5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-Methyl-MORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-Triazol-3-Amine In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 5 patents in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
Every application published under this name has become a patent.